Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tucidinostat + apatinib
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of tucidinostat (formerly known as chidamide), an orally available selective histone deacetylase (HDAC) inhibitor that targets HDAC1, 2, 3, and 10, and apatinib, a tyrosine kinase inhibitor primarily targeting vascular endothelial growth factor receptor-2 (VEGFR-2). This combination is being investigated for its potential synergistic effects in treating various cancers, particularly relapsed or refractory osteosarcoma and advanced esophageal cancer.
- Other names
- ChidamideRivoceranibTucidinostat and Apatinib
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on tucidinostat + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tucidinostat + apatinib.